secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCorRx Inc. (BICX)
CIK:        0001443863
Form:       8-K
Filed at:   2021-09-02T23:59:59+00:00
Accession:  0001477932-21-006115
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCorRx awarded $3.5M NIDA grant for first-in-human trial of BICX104 implant
-----------------------------------------------------------------------------

- Award of ~$3.5M from NIDA for second phase (UH3) of grant; total NIDA funding now ~$5.7M.
- Funding supports first-in-human clinical trial of BICX104, an implantable naltrexone pellet for opioid use disorder.
- Company previously received FDA clearance to proceed to human trials; aims to begin trial in 2021.
- Grant is non-dilutive, covering substantial costs toward FDA approval for BICX104.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1443863/000147793221006115/0001477932-21-006115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1443863/000147793221006115/bicx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-21-006115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer